Aiolos Bio: GSK to pump 200 million into UK to boost medicine production and buys Aiolos Bio for $1.1 billion
Pharma giant, GSK, plans to invest Â200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (Â870 million).
Read full article »
Aiolos Bio is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases.
Read more